127 related articles for article (PubMed ID: 18304900)
1. The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients.
Ouerhani S; Marrakchi R; Bouhaha R; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; El Gaaied AB
Bull Cancer; 2008 Feb; 95(2):E1-4. PubMed ID: 18304900
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India.
Sobti RC; Al-Badran AI; Sharma S; Sharma SK; Krishan A; Mohan H
Cancer Genet Cytogenet; 2005 Jan; 156(1):68-73. PubMed ID: 15588859
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of CYP2D6 and lung cancer risk.
Shaw GL; Falk RT; Frame JN; Weiffenbach B; Nesbitt JC; Pass HI; Caporaso NE; Moir DT; Tucker MA
Cancer Epidemiol Biomarkers Prev; 1998 Mar; 7(3):215-9. PubMed ID: 9521436
[TBL] [Abstract][Full Text] [Related]
4. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 genotype and the incidence of anal and vulvar cancer.
Chen C; Cook LS; Li XY; Hallagan S; Madeleine MM; Daling JR; Weiss NS
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):317-21. PubMed ID: 10207635
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors.
Gomes L; Lemos MC; Paiva I; Ribeiro C; Carvalheiro M; Regateiro FJ
Acta Med Port; 2005; 18(5):339-43. PubMed ID: 16611538
[TBL] [Abstract][Full Text] [Related]
7. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility.
Tasci AI; Tugcu V; Ozbek E; Ozbay B; Simsek A; Koksal V
BJU Int; 2008 Feb; 101(4):503-7. PubMed ID: 17986285
[TBL] [Abstract][Full Text] [Related]
8. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder.
Vázquez-Lavista LG; Lima G; Gabilondo F; Llorente L
Urology; 2009 Aug; 74(2):414-8. PubMed ID: 19646633
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in one-carbon metabolism pathway genes and risk for bladder cancer in a Tunisian population.
Rouissi K; Ouerhani S; Oliveira E; Marrakchi R; Cherni L; Ben Othman F; Ben Slama MR; Sfaxi M; Ayed M; Chebil M; Amorim A; Prata MJ; Benammar Elgaaied A
Cancer Genet Cytogenet; 2009 Nov; 195(1):43-53. PubMed ID: 19837268
[TBL] [Abstract][Full Text] [Related]
10. Influence of XPD and APE1 DNA repair gene polymorphism on bladder cancer susceptibility in north India.
Gangwar R; Ahirwar D; Mandhani A; Mittal RD
Urology; 2009 Mar; 73(3):675-80. PubMed ID: 19041121
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-4 gene intron-3 polymorphism is associated with transitional cell carcinoma of the urinary bladder.
Tsai FJ; Chang CH; Chen CC; Hsia TC; Chen HY; Chen WC
BJU Int; 2005 Feb; 95(3):432-5. PubMed ID: 15679809
[TBL] [Abstract][Full Text] [Related]
13. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
[TBL] [Abstract][Full Text] [Related]
14. HLA-G polymorphism and transitional cell carcinoma of the bladder in a Brazilian population.
Castelli EC; Mendes-Junior CT; Viana de Camargo JL; Donadi EA
Tissue Antigens; 2008 Aug; 72(2):149-57. PubMed ID: 18721275
[TBL] [Abstract][Full Text] [Related]
15. The association of CYP2D6 *10 polymorphism with breast cancer risk and clinico-pathologic characteristics in Chinese women.
Li H; Feng L; Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Li J; Xie Y
Acta Oncol; 2006; 45(5):597-601. PubMed ID: 16864175
[TBL] [Abstract][Full Text] [Related]
16. DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder.
Ma X; Xu H; Zheng T; Li HZ; Shi TP; Wang BJ; Ju ZH; Wang C; Zhang GX; Zhang X
BJU Int; 2008 Aug; 102(5):633-6. PubMed ID: 18384629
[TBL] [Abstract][Full Text] [Related]
17. Significant association of XPD codon 312 single nucleotide polymorphism with bladder cancer susceptibility in Taiwan.
Chang CH; Wang RF; Tsai RY; Wu HC; Wang CH; Tsai CW; Chang CL; Tsou YA; Liu CS; Bau DT
Anticancer Res; 2009 Oct; 29(10):3903-7. PubMed ID: 19846926
[TBL] [Abstract][Full Text] [Related]
18. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR.
McKeown-Eyssen G; Baines C; Cole DE; Riley N; Tyndale RF; Marshall L; Jazmaji V
Int J Epidemiol; 2004 Oct; 33(5):971-8. PubMed ID: 15256524
[TBL] [Abstract][Full Text] [Related]
19. CYP 2D6 polymorphism: a predictor of susceptibility and response to chemoradiotherapy in head and neck cancer.
Shukla P; Gupta D; Pant MC; Parmar D
J Cancer Res Ther; 2012; 8(1):40-5. PubMed ID: 22531512
[TBL] [Abstract][Full Text] [Related]
20. Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition.
Yang H; Gu J; Lin X; Grossman HB; Ye Y; Dinney CP; Wu X
Clin Cancer Res; 2008 Apr; 14(7):2236-44. PubMed ID: 18381966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
